{"organizations": [], "uuid": "ae70d9b940283a902394a013a7f79a20eccf6649", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mylan-receives-tentative-approval/brief-mylan-receives-tentative-approval-for-combination-hiv-treatment-dtg-ftc-taf-under-fdas-pepfar-program-idUSASB0C6D8", "country": "US", "domain_rank": 408, "title": "BRIEF-Mylan Receives Tentative Approval For Combination HIV Treatment DTG/FTC/TAF Under FDA's Pepfar Program", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.996, "site_type": "news", "published": "2018-02-20T20:53:00.000+02:00", "replies_count": 0, "uuid": "ae70d9b940283a902394a013a7f79a20eccf6649"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mylan-receives-tentative-approval/brief-mylan-receives-tentative-approval-for-combination-hiv-treatment-dtg-ftc-taf-under-fdas-pepfar-program-idUSASB0C6D8", "ord_in_thread": 0, "title": "BRIEF-Mylan Receives Tentative Approval For Combination HIV Treatment DTG/FTC/TAF Under FDA's Pepfar Program", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "pepfar program", "sentiment": "negative"}, {"name": "mylan", "sentiment": "negative"}, {"name": "mylan nv", "sentiment": "negative"}, {"name": "pepfar", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Mylan Nv:\n* MYLAN RECEIVES TENTATIVE APPROVAL FOR COMBINATION HIV TREATMENT DTG/FTC/TAF UNDER FDA‘S PEPFAR PROGRAM\n* MYLAN NV - ‍ ANTIRETROVIRAL WILL BE IMMEDIATELY AVAILABLE IN DEVELOPING COUNTRIES AS A FIRST-LINE REGIMEN FOR PEOPLE BEING TREATED FOR HIV/AIDS​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T20:53:00.000+02:00", "crawled": "2018-02-21T21:40:45.012+02:00", "highlightTitle": ""}